Fresh from signing a deal to supply Switzerland and Singapore with enough avian flu vaccine to inoculate the country's entire population, GlaxoSmithKline is now in talks to sign similar deals with France and the U.K. The vaccine has not yet been approved, but the EMEA's stamp of approval is expected in a matter of weeks. Some concerns have been raised that the new vaccine may not be effective against any new strain of avian flu that may trigger a human pandemic. Report